In fact, a small increase in BMD of the lumbar spine during the first year of treatment was recorded, regardless of the use of GCs. Acknowledgments The authors thank all participating research nurses of the Utrecht Rheumatoid Arthritis
Cohort study group for data collection, A.W.J.M. Jacobs-van Bree for data entry, S.M. Sijbers-Klaver for data management, and A.A. van Everdingen, MD, PhD, for scoring radiographs. Funding The CAMERA-II study was financially supported by an unrestricted grant of the Dutch funding organization ‘Catharijne Stichting’. Conflicts of interest None. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommrcial use, distribution, and reproduction in any medium, provided the original author(s) and the source are Selleckchem GW572016 credited. References 1. Sokka T,
Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, Skakic V, Badsha H, Peets T, Baranauskaite A, Geher P, Ujfalussy I, Skopouli FN, Mavrommati M, Alten R, Pohl C, Sibilia J, Stancati A, Salaffi F, Romanowski W, Zarowny-Wierzbinska D, Henrohn D, Bresnihan B, Minnock P, Knudsen LS, Jacobs JW, Calvo-Alen J, Lazovskis J, Pinheiro Gda R, Karateev D, Andersone D, Rexhepi S, Yazici Y, Pincus T (2009) Women, men, and rheumatoid arthritis: analyses of disease activity, selleck chemical disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 11(1):R7PubMed 2. Kirwan JR (1995) 3-oxoacyl-(acyl-carrier-protein) reductase The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333(3):142–146PubMedCrossRef 3. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine
with sulphasalazine alone in early rheumatoid arthritis. Lancet 350(9074):309–318PubMedCrossRef 4. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side BI 10773 effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136(1):1–12PubMed 5. Wassenberg S, Rau R, Steinfeld P, Zeidler H (2005) Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 52(11):3371–3380PubMedCrossRef 6.